Humoral Immunity to Measles, Mumps, Rubella, Diphtheria, Tetanus and Pertussis After Cancer Treatment in Children

Area of Science:

• Pediatric Oncology
• Immunology
• Vaccinology

Background:

• Pediatric cancer treatments significantly impact immune system function.
• Understanding post-treatment immune status is crucial for patient recovery and long-term health.

Purpose of the Study:

• To evaluate humoral immunity against measles, mumps, and rubella (MMR) and diphtheria, tetanus, and acellular pertussis (DTaP) vaccines in children post-cancer treatment.
• To identify specific vaccine antigens where antibody levels may decline after therapy.

Main Methods:

• Assessed IgG antibody titers in 52 children against MMR and DTaP vaccine antigens.
• Measurements were taken after completion of cancer treatment.

Main Results:

• A significant proportion of children exhibited below-reference IgG titers for pertussis, diphtheria, and tetanus antigens post-treatment.
• Conversely, only a small number of subjects had low titers against measles, mumps, and rubella antigens.
• Immune response varied between different vaccine types after therapy.

Conclusions:

• Cancer treatment in children can lead to diminished immunity against certain vaccine-preventable diseases, particularly DTaP components.
• Findings suggest a need to reconsider and potentially adapt re-vaccination strategies for pediatric cancer survivors.
• Monitoring vaccine-induced immunity is essential for managing long-term health in this population.